Companies › Nektar Therapeutics
1 active drug program in 4 registered trials: 2 Phase 3, 2 Phase 2; Immunology, Metabolic and endocrine; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Rezpegaldesleukin (NKTR-358) Pegylated recombinant human interleukin-2 | IL2RA, IL2 | Phase 3 | Moderate-to-Severe Atopic Dermatitis; Moderate to Severe Atopic Dermatitis; Type 1 Diabetes Mellitus | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06136741 | Rezpegaldesleukin (NKTR-358) | Phase 2 | Moderate to Severe Atopic Dermatitis | Immunology | Dec 2026 |
| NCT07690371 | Rezpegaldesleukin (NKTR-358) | Phase 3 | Moderate-to-Severe Atopic Dermatitis | Immunology | May 2028 |
| NCT07142252 | Rezpegaldesleukin (NKTR-358) | Phase 2 | Type 1 Diabetes Mellitus | Metabolic and endocrine | May 2028 |
| NCT07711418 | Rezpegaldesleukin (NKTR-358) | Phase 3 | Moderate-to-Severe Atopic Dermatitis | Immunology | Jun 2028 |
Cash and short-term investments of $684m on 2026-06-30; operating cash outflow about $243m a year; runway about 34 months at that burn, to Apr 2029; 4 of 4 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Regeneron Pharmaceuticals Synthekine Mural Oncology PolTREG GI Innovation AgonOx CellTrans Innovent Biologics (Suzhou) AstraZeneca Medicenna Therapeutics
Abeona Therapeutics Doron Therapeutics UnicoCell Biomed Ascendis Pharma Bone Diseases BioXTek
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.